TY - JOUR
T1 - The effect of salsalate therapy on endothelial function in a broad range of subjects.
AU - Nohria, Anju
AU - Kinlay, Scott
AU - Buck, J. Stewart
AU - Redline, Whitney
AU - Copeland-Halperin, Robert
AU - Kim, Sora
AU - Beckman, Joshua A.
PY - 2014
Y1 - 2014
N2 - Inflammation is fundamental to the development of atherosclerosis. We examined the effect of anti-inflammatory doses of salicylate on endothelium-dependent vasodilation, a biomarker of cardiovascular risk, in a broad range of subjects. We performed a randomized, double-blind, placebo-controlled crossover trial evaluating the effects of 4 weeks of high-dose salsalate (disalicylate) therapy on endothelium-dependent flow-mediated and endothelium-independent vasodilation. Fifty-eight subjects, including 17 with metabolic syndrome, 13 with atherosclerosis, and 28 healthy controls, were studied. Among all subjects, endothelium-dependent flow-mediated vasodilation decreased after salsalate compared with placebo therapy (P=0.01), whereas nitroglycerin-mediated, endothelium-independent vasodilation was unchanged (P=0.97). Endothelium-dependent flow-mediated vasodilation after salsalate therapy was impaired compared with placebo therapy in subjects with therapeutic salicylate levels (n=31, P<0.02) but not in subjects with subtherapeutic levels (P>0.2). Salsalate therapy, particularly when therapeutic salicylate levels are achieved, impairs endothelium-dependent vasodilation in a broad range of subjects. These data raise concern about the possible deleterious effects of anti-inflammatory doses of salsalate on cardiovascular risk. www.clinicaltrials.gov. Unique Identifiers: NCT00760019 and NCT00762827.
AB - Inflammation is fundamental to the development of atherosclerosis. We examined the effect of anti-inflammatory doses of salicylate on endothelium-dependent vasodilation, a biomarker of cardiovascular risk, in a broad range of subjects. We performed a randomized, double-blind, placebo-controlled crossover trial evaluating the effects of 4 weeks of high-dose salsalate (disalicylate) therapy on endothelium-dependent flow-mediated and endothelium-independent vasodilation. Fifty-eight subjects, including 17 with metabolic syndrome, 13 with atherosclerosis, and 28 healthy controls, were studied. Among all subjects, endothelium-dependent flow-mediated vasodilation decreased after salsalate compared with placebo therapy (P=0.01), whereas nitroglycerin-mediated, endothelium-independent vasodilation was unchanged (P=0.97). Endothelium-dependent flow-mediated vasodilation after salsalate therapy was impaired compared with placebo therapy in subjects with therapeutic salicylate levels (n=31, P<0.02) but not in subjects with subtherapeutic levels (P>0.2). Salsalate therapy, particularly when therapeutic salicylate levels are achieved, impairs endothelium-dependent vasodilation in a broad range of subjects. These data raise concern about the possible deleterious effects of anti-inflammatory doses of salsalate on cardiovascular risk. www.clinicaltrials.gov. Unique Identifiers: NCT00760019 and NCT00762827.
UR - http://www.scopus.com/inward/record.url?scp=84898609032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898609032&partnerID=8YFLogxK
U2 - 10.1161/JAHA.113.000609
DO - 10.1161/JAHA.113.000609
M3 - Article
C2 - 24390146
AN - SCOPUS:84898609032
SN - 2047-9980
VL - 3
SP - e000609
JO - Journal of the American Heart Association
JF - Journal of the American Heart Association
IS - 1
ER -